Special Issue

Conceptual Breakthrough of Noncoding RNAs in Biomedicine

Message from the Guest Editor

This Special Issue aims to collect high-quality papers addressing the concept of the noncoding RNA (ncRNA) functional system and its role in biomedicine. The conventional understanding of ncRNA functions is largely derived from protein-driven systems derived from organisms with limited noncoding regions, such as E. coli and yeast. Recent big data studies revealed that ncRNAs possess a unique functional system distinctive from the protein-based system, and proteins only work in the normal physiological state, whereas ncRNAs play much broader, critical roles than originally thought when coping with a wide array of abnormal physiological states such as cancers. The protein-based concept of ncRNA function is inappropriate for understanding their roles in biomedicine. New breakthrough concepts have become critical in advancing our understanding of ncRNA functions.

Guest Editor

Dr. Anyou Wang

Feinstone Center for Genomic Research, The University of Memphis, Memphis, TN, USA

Deadline for manuscript submissions

closed (30 April 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/149003

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).